FOI 2637 2022/23
Usage of high cost drugs in Ophthalmology and Metabolic diseases
Published 01 September 2023
Usage of high cost drugs in Ophthalmology and Metabolic diseases
Questions
- For the 4 months from May to August 2022, how many patients received the following anti-VEGF treatments for any eye condition:
- For the patients above, how many were new to anti-VEGF therapy? Please provide the patient numbers by the treatments listed below, excluding patients who previously had any anti-VEGF therapy.
- How many patients have you treated in the last 12 months with the following drugs?
Response
Please note – this response covers four hospitals.
QE = Queen Elizabeth Hospital Birmingham
HGS = Heartlands, Good Hope and Solihull Hospitals
1.
|
Drug |
Number_of_patients QE |
Number_of_patients HGS |
|
Aflibercept |
<6 |
issued to clinics as stock (clinics hold patient information)
|
|
Bevacizumab |
80 |
20 |
|
Brolucizumab |
0 |
0 |
|
Dexamethasone |
5624 |
20- also issued to clinics as stock
|
|
Faricimab |
0 |
0 |
|
Ranibizumab – Lucentis |
0 |
issued to clinics as stock(clinics hold patient information)
|
|
Ranibizumab – Ongavia |
0 |
0 |
2.
|
Drug |
Number_of_patients QE |
Number_of_patients HGS |
|
Aflibercept |
Not held |
issued to clinics as stock (clinics hold patient information)
|
|
Bevacizumab |
Not held |
8 |
|
Brolucizumab |
Not held |
0 |
|
Dexamethasone |
Not held |
15( also issued to clinics as stock)
|
|
Faricimab |
Not held |
0 |
|
Ranibizumab – Lucentis |
Not held |
issued to clinics as stock(clinics hold patient information)
|
|
Ranibizumab – Ongavia |
Not held |
0 |
3.
|
Drug |
Number_of_patients UHB |
Number_of_patients HGS |
|
Genotropin |
12 |
9 |
|
Humatrope |
1 |
1 |
|
Norditropin |
24 |
22 |
|
Nutropin |
9 |
11 |
|
Omnitrope |
0 |
0 |
|
Saizen |
9 |
9 |
|
Zomacton |
1 |
1 |
|
Any other Somatropin (please specify) |
57 (Somatropin) |
0 |